Efektivitas Citicoline sebagai Terapi Gangguan Kognitif pada Stroke Iskemik Akut
DOI:
https://doi.org/10.55175/cdk.v51i2.971Keywords:
Citicoline, cognitive, strokeAbstract
Background: Cognitive impairment in acute ischemic stroke is associated with disability, poor functional outcome, and mortality, hence requires effective management. Citicoline is one of pharmacotherapy for central nervous system disorders. This study aims to evaluate current evidence of the effectiveness of citicoline for cognitive impairment in acute ischemic stroke. Methods: Systematic review and meta-analysis on randomized controlled trials searched in PubMed, Cochrane, and Google Scholar databases. Screening was done on 518 articles according to inclusion and exclusion criteria, 3 articles were qualified for review. Results: Cano-Cuenca, et al, (2015) found that citicoline was associated with a mini-mental state examination (MMSE) score of >25 at 12 weeks. Pinzon & Asanyi (2018) found that the use of citicoline can prevent cognitive impairment at 6 and 12 months, especially in attention and temporal orientation. Bonvicini, et al, (2022) found that citicoline is associated with good cognitive outcomes as measured with global cognitive impairment. Conclusion: Citicoline is effective as a therapy for cognitive impairment in acute ischemic stroke.
Downloads
References
Esmael A, Elsherief M, Eltoukhy K. Prevalence of cognitive impairment in acute ischaemic stroke and use of Alberta Stroke Programme Early CT Score (ASPECTS) for early prediction of post-stroke cognitive impairment. Neurol Neurochir Pol. 2021;55:179–85.
Droś J, Kowalska K, Pasińska P, Klimkowicz-Mrowiec A. Transient cognitive impairment in the acute phase of stroke – prevalence, risk factors and influence on long-term prognosis in population of patients with stroke (research study – part of the PROPOLIS study). BMC Neurol. 2023;23:75.
Pinzon RT, Anggraini C. The predictor factors of cognitive disorders thirty days post mild-moderate ischemic stroke 2018. J Indon Med Assoc. 2021;71:5
Li J, Wang J, Wu B, Xu H, Wu X, Zhou L, et al. Association between early cognitive impairment and midterm functional outcomes among Chinese acute ischemic stroke patients: A longitudinal study. Front Neurol. 2020;11:20
Agarwal S, Patel BM. Is Aura of Citicoline Faded Out Systemic Review. Indian J Pharmacol. 2017;49:4–9
Jasielski P, Piedel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of citicoline in neurological disorders: A systematic review. Nutrients 2020;12:1–20.
Premi E, Cantoni V, Benussi A, Gilberti N, Vergani V, Delrio I, et al. Citicoline treatment in acute ischemic stroke: A randomized, single-blind TMS study. Front Neurol. 2022;13:915362
Harrison JK, Reid J Quinn TJ. Shenkin SD. Using quality assessment tools to critically appraise ageing research: A guide for clinicians. Age Ageing 2017;46:359–365.
Mohd Zulkifly MF, Ghazali SE, Che Din N, Singh DKA, Subramaniam P. A review of risk factors for cognitive impairment in stroke survivors. Scient World J. 2016:3456943. DOI: 10.1155/2016/3456943
El Husseini N, Katzan IL, ROst NS, Blake ML, Byun E, Pendlebury ST, et al. Cognitive impairment after ischemic and hemorrhagic stroke: A scientific statement from the American Heart Association/American Stroke Association. Stroke. 2023;54:e272–e291
Cano-Cuenca N, Solís-García del Pozo J, Jordán J. Citicoline efficiency on cognitive function: A systematic review. J Aging Res Lifestyle. 2015;4:1–12. DOI:10.14283/jarcp.2015.79.
Bonvicini M, Travaglini S, Lelli D, Antonelli Incalzi R, Pedone C. Is citicoline effective in preventing and slowing down dementia?—A systematic review and a meta-analysis. Nutrients 2023;15:386.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Lothar Matheus Manson Vanende Silalahi, Pradita Sri Mitasari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.